Cerecin Partners with NIHR HealthTech Research Centre
Cerecin is thrilled to announce its collaboration with the NIHR HealthTech Research Centre in Brain Health. This prestigious partnership sees the company join esteemed entities like GE Healthcare and Novo Nordisk, aiming to innovate in the realm of dementia care.
About the NIHR HealthTech Research Centre
The NIHR HealthTech Research Centre, hosted at a major academic institution, is committed to enhancing the standards of dementia diagnosis and treatment methods. By harnessing advanced technologies such as brain imaging, blood analysis, and digital testing tools, their goal is to create early intervention strategies for dementia, thereby mitigating its far-reaching societal effects.
Leadership Driving the Initiative
This initiative is spearheaded by leading figures in neuroscience, including esteemed professors known for their cutting-edge contributions to brain health. Their combined expertise aims to merge academic research with industry practices, addressing some of neuroscience's most pressing challenges.
Insights from Cerecin's CEO
Dr. Charles Stacey, the President & CEO of Cerecin, expressed enthusiasm about the collaboration, highlighting that King’s College London’s reputation in neuroscience makes this partnership a significant step forward. He emphasized the importance of academic and industry synergy in fostering innovation and delivering impactful solutions.
Expert Opinions on the Collaboration
Dr. Richard Siow, who oversees Ageing Research at King’s, also welcomed Cerecin into the partnership. He pointed out the pivotal role that neurometabolism plays in advancing the frontiers of neuroscience, asserting that their combined efforts can drive revolutionary advancements in brain health care.
The ALTER AD Study and Focus Areas
Cerecin is pushing forward with the ALTER AD study, a crucial Phase 3 clinical program aimed at tackling Alzheimer's disease through its innovative lead compound, tricaprilin. As they seek to enhance their leadership in this sector, strategic partnerships will play a vital role in developing current projects and ushering in future innovations in neurological health.
About Cerecin
Cerecin operates as a clinical-stage biotechnology company specializing in the metabolic underpinnings of neurological disorders. With a wealth of experience and strong support from multinational corporations, Cerecin is positioning itself as a leader in the realm of neurology therapeutics.
Innovative Approach with Tricaprilin
Tricaprilin, their flagship compound currently undergoing Phase 3 evaluation, works by enhancing ketone production through the direct delivery of medium-chain fatty acids. This mechanism tailors energy production pathways to improve function in cells that are struggling due to impaired glucose metabolism.
Frequently Asked Questions
What is Cerecin's role in the partnership with NIHR?
Cerecin is an industry partner collaborating with NIHR HealthTech to advance research and treatment options for brain health.
What is the focus of the NIHR HealthTech Research Centre?
The Centre is dedicated to improving dementia diagnosis and care using advanced technologies.
Who leads the NIHR HealthTech Research Centre?
The Centre is led by prominent scholars in neuroscience focused on innovative approaches to dementia treatment.
What is the ALTER AD study?
The ALTER AD study is Cerecin's Phase 3 clinical trial investigating tricaprilin's effects on Alzheimer's disease.
What unique benefits does tricaprilin provide?
Tricaprilin enhances ketone production, supporting energy production in cells affected by impaired glucose metabolism.
